First Horizon Advisors Inc. Decreases Holdings in Sanofi (NASDAQ:SNY)

First Horizon Advisors Inc. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 7.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,235 shares of the company’s stock after selling 409 shares during the quarter. First Horizon Advisors Inc.’s holdings in Sanofi were worth $260,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Rise Advisors LLC boosted its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new position in shares of Sanofi in the fourth quarter worth $27,000. Venturi Wealth Management LLC boosted its position in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after buying an additional 332 shares during the period. McIlrath & Eck LLC grew its holdings in Sanofi by 143.3% in the 4th quarter. McIlrath & Eck LLC now owns 613 shares of the company’s stock worth $30,000 after acquiring an additional 361 shares during the last quarter. Finally, CNB Bank bought a new position in shares of Sanofi during the third quarter valued at about $39,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

SNY opened at $49.01 on Monday. The firm has a market cap of $123.98 billion, a PE ratio of 24.63, a P/E/G ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The stock has a 50-day moving average price of $47.90 and a 200-day moving average price of $48.16. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.93.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Sell-side analysts predict that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a dividend of $1.478 per share. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 69.35%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley started coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.